Anti-B7-H3 antibody is well-tolerated Single-agent, anti-tumor activity observed across several tumor types Initial evidence of T-cell immunomodulatory role ROCKVILLE, Md. , Nov. 07, 2015 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on

Second paper published demonstrating DART molecule potential against HIV Data support HIV research contract recently awarded to MacroGenics by NIAID ROCKVILLE, Md. , Nov. 05, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering

Bi-specific antibody leadership — fifth DART® molecule (MGD009) enters clinical testing B7-H3 franchise advances — Encouraging initial clinical results from ongoing enoblituzumab (MGA271) Phase 1 trial and regional rights regained  Recent collaboration with Merck on immuno-oncology study evaluating

ROCKVILLE, Md. , Nov. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

Rockville, MD , Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, November 4, 2015 , the Company will release its financial results for the quarter ended September 30, 2015 . The Company's management team will host a conference call discussing the

Servier does not exercise option to license rights for enoblituzumab in its specified territories MacroGenics advances enoblituzumab and pursues integrated B7-H3 franchise strategy Rockville, MD , Oct. 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a clinical-stage

Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer

Encouraging initial clinical results from ongoing enoblituzumab (MGA271) trial B7-H3 franchise extended — fifth DART® molecule (MGD009) in Phase 1 Proprietary immune checkpoint PD-1 x LAG-3 DART molecule (MGD013) introduced HIV DART and Trident™ tri-specific platform introduced ROCKVILLE, Md.

--Company to provide in-depth review of its antibody-based technology platforms and broad portfolio of therapeutics being developed to treat cancer, autoimmune disorders and infectious diseases

ROCKVILLE, Maryland , Oct. 01, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Md. , Sept. 22, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

MacroGenics to Participate in Two Upcoming Investor Conferences ROCKVILLE, Md., Sept. 03, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of

-- Fourth bi-specific DART® molecule, MGD011, in clinical testing         -- Margetuximab Phase 3 SOPHIA metastatic breast cancer study initiated         -- Balance sheet strengthened with completion of $141 million equity offering ROCKVILLE, Md. , Aug.

Rockville, MD , Aug. 04, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Md , July 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, August 5, 2015 , the Company will release its financial results for the quarter ended June 30, 2015 . The Company's management team will host a conference call discussing the

—  Triggers $10 million milestone payment from Janssen  —  Fourth DART® molecule to enter the clinic in last 12 months ROCKVILLE, Md. , July 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc.  (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative

ROCKVILLE, Md. , July 14, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Md. , July 13, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

Data Show Signs of Clinical Activity for Margetuximab in HER2-Expressing Tumors

—    MGD006 Enables T Cells to Recognize and Kill Leukemia Cells —     Research Paved the Way for Human Clinical Trials ROCKVILLE, Md. , May 27, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative

Company to Present Updated Findings From Its Phase 1 Study of Margetuximab

-- Company's third bi-specific DART® molecule, MGD010, in clinical testing -- FDA clears IND for fourth DART, MGD011 - Janssen to initiate clinical testing -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 ROCKVILLE, Md.

ROCKVILLE, Md. , April 29, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Wednesday, May 6, 2015 , the Company will release its financial results for the quarter ended March 31, 2015 . The Company's management team will host a conference call discussing the

ROCKVILLE, Md. , April 28, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious

ROCKVILLE, Md. , April 20, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious